Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 8/20 | 0.77 |
| ▸ | ERN1 | O75460 | 7/20 | 0.77 |
| ▸ | TEK | Q02763 | 12/20 | 0.77 |
| ▸ | KDR | P35968 | 9/20 | 0.77 |
| ▸ | AURKA | O14965 | 7/20 | 0.77 |
| ▸ | LCK | P06239 | 7/20 | 0.77 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973648 | 0.99 | MAPK10 (0.76) | MAPK10ERN1TEKKDRAURKA | |
| SCHEMBL974406 | 0.90 | MAPK10 (0.75) | MAPK10ERN1TEKKDRAURKA | |
| SCHEMBL973288 | 0.89 | MAPK10 (0.75) | MAPK10ERN1TEKKDRAURKA | |
| SCHEMBL974094 | 0.87 | TEK (1.00) | MAPK10ERN1TEKKDRAURKA | |
| SCHEMBL973093 | 0.84 | TEK (1.00) | MAPK10ERN1TEKKDRAURKA | |
| SCHEMBL973870 | 0.84 | TEK (1.00) | MAPK10ERN1TEKKDRAURKA | |
| SCHEMBL973994 | 0.82 | MAPK10 (0.84) | MAPK10ERN1TEKKDRAURKA | |
| SCHEMBL973150 | 0.80 | TEK (1.00) | MAPK10ERN1TEKKDRAURKA | |
| SCHEMBL973703 | 0.79 | TEK (0.87) | MAPK10ERN1TEKKDRAURKA | |
| SCHEMBL972319 | 0.78 | TEK (0.77) | MAPK10ERN1TEKKDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868177-B2 | Multi-cyclic compounds and method of use | AMGEN INC. (US) | 2011-01-11 | — | — | US | claimed |
| EP-1994030-B1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2010-08-25 | — | — | EP | claimed |
| EP-1994030-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | Amgen Inc. (US) | 2008-11-26 | — | — | EP | claimed |
| US-20070213325-A1 | Multi-cyclic compound and method of use | AMGEN INC. (US) | 2007-09-13 | — | — | US | claimed |
| WO-2007100646-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2007-09-07 | — | — | WO | claimed |
| EP-1994030-B1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213325-A1 | Multi-cyclic compound and method of use | TIE1, CDK1, CCNB1 | MAPK10 1014/4885ERN1 1756/4885TEK 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.